144 related articles for article (PubMed ID: 37067398)
1. Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancer.
Yang XR; Pi C; Zhang YC; Chen ZH; Zhang XC; Zhu DQ; Yang LL; Yin JC; Deng JY; Yang MY; Luo WC; Wu YL; Zhou Q
Mol Carcinog; 2023 Jul; 62(7):1001-1008. PubMed ID: 37067398
[TBL] [Abstract][Full Text] [Related]
2. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
3. Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma.
Xiao G; Li L; Tanzhu G; Liu Z; Gao X; Wan X; Xiao D; Chen L; Xia X; Zhou R
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36868569
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma.
Zhou P; Chen D; Zhu B; Chen W; Xie Q; Wang Y; Tan Q; Yuan B; Zuo X; Huang C; Zhu H; Li G
Front Immunol; 2020; 11():594212. PubMed ID: 33552051
[TBL] [Abstract][Full Text] [Related]
5. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer.
Kudo Y; Haymaker C; Zhang J; Reuben A; Duose DY; Fujimoto J; Roy-Chowdhuri S; Solis Soto LM; Dejima H; Parra ER; Mino B; Abraham R; Ikeda N; Vaporcyan A; Gibbons D; Zhang J; Lang FF; Luthra R; Lee JJ; Moran C; Huse JT; Kadara H; Wistuba II
Ann Oncol; 2019 Sep; 30(9):1521-1530. PubMed ID: 31282941
[TBL] [Abstract][Full Text] [Related]
6. Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications.
Del Conte A; De Carlo E; Bertoli E; Stanzione B; Revelant A; Bertola M; Spina M; Bearz A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743275
[TBL] [Abstract][Full Text] [Related]
7. Immune Infiltration in Tumor and Adjacent Non-Neoplastic Regions Codetermines Patient Clinical Outcomes in Early-Stage Lung Cancer.
Cheng C; Nguyen TT; Tang M; Wang X; Jiang C; Liu Y; Gorlov I; Gorlova O; Iafrate J; Lanuti M; Christiani DC; Amos CI
J Thorac Oncol; 2023 Sep; 18(9):1184-1198. PubMed ID: 37146750
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma.
Li C; Zheng X; Li P; Wang H; Hu J; Wu L; Wang Z; Guo H; Wu F; Zhong W; Zhou C; Chu Q; Zhao J; Zheng X; Xiao W; Zhu W; Zhang L; Li Q; Jiang K; Miao Q; Wu B; Xu Y; Wu S; Wang H; Yang S; Li Y; Xia X; Yi X; Huang C; Zhu B; Lin G
Front Immunol; 2022; 13():944812. PubMed ID: 36032124
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
Front Immunol; 2022; 13():974581. PubMed ID: 36159860
[TBL] [Abstract][Full Text] [Related]
10. Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer.
Duan J; Lv G; Zhu N; Chen X; Shao Y; Liu Y; Zhao W; Shi Y
Thorac Cancer; 2022 Apr; 13(7):947-955. PubMed ID: 35150094
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis.
Song Z; Yang L; Zhou Z; Li P; Wang W; Cheng G; Chen R; Chang L; Zhang Y; Guan Y; Xia X; Yi X; Zhou R; Chen M
Cell Death Dis; 2021 Jan; 12(1):106. PubMed ID: 33479213
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
Front Immunol; 2021; 12():697298. PubMed ID: 34858389
[TBL] [Abstract][Full Text] [Related]
14. [Correlation between Immune Microenvironment Features and EGFR Mutation Status
in Lung Adenocarcinoma].
Zhu H; Chen P; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Yuan F; Yu X; Sun Q; Ji J; Wang S; Liu T; Xu L
Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):204-216. PubMed ID: 37035883
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the ferroptosis-related prognostic biomarker and immune microenvironment of driver gene-negative lung cancer.
Zhou R; Ma HC; Liu YH; Chen X; Chang XS; Chen YD; Liu LR; Li Y; Zhu YJ; Zhang HB
Exp Biol Med (Maywood); 2022 Aug; 247(16):1447-1465. PubMed ID: 35762414
[TBL] [Abstract][Full Text] [Related]
16. Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays "cold" immune characteristics in Non-small cell lung cancer.
Zhu YJ; Chang XS; Zhou R; Chen YD; Ma HC; Xiao ZZ; Qu X; Liu YH; Liu LR; Li Y; Yu YY; Zhang HB
Lung Cancer; 2022 Apr; 166():189-196. PubMed ID: 35306320
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer.
Fang Y; Wang Y; Zeng D; Zhi S; Shu T; Huang N; Zheng S; Wu J; Liu Y; Huang G; Xue Y; Bin J; Liao Y; Shi M; Liao W
Oncoimmunology; 2021; 10(1):1951019. PubMed ID: 34345533
[TBL] [Abstract][Full Text] [Related]
18. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
Front Immunol; 2022; 13():834142. PubMed ID: 35242138
[TBL] [Abstract][Full Text] [Related]
19. [Application of Immune Checkpoint Inhibitors in EGFR Mutant
Advanced Non-small Cell Lung Cancer].
Zheng Y; Jiang W; Li J; Dai L; Chen D; Li Y; Huang L; Wang M
Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):671-677. PubMed ID: 36172732
[TBL] [Abstract][Full Text] [Related]
20. Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor.
Öjlert ÅK; Nebdal D; Snapkov I; Olsen V; Kidman J; Greiff V; Chee J; Helland Å
Mol Oncol; 2021 Nov; 15(11):2958-2968. PubMed ID: 34402187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
